<div id="readability-page-1"><div><p>[SINGAPORE] A privatisation offer for medical services company Singapore Paincare has fallen through, as the offeror, Advance Bridge Healthcare, was unable to satisfy the conditions of the scheme of arrangement by its expiry date of Nov 27.</p><p>The companies added on Friday (Dec 5) that the credit facilities between Advance Bridge Healthcare, a management consultancy for healthcare services, and UOB also lapsed after Nov 27.</p><p>Therefore, the confirmation that the offeror possesses sufficient financial resources to satisfy in full the aggregate scheme consideration payable for all the scheme shared to be acquired has lapsed.</p><p>The cut-off date to satisfy the scheme conditions will not be extended, as Advance Bridge Healthcare does not have available assets, funds or collateral to support a fresh financial resources confirmation, and does not expect that it will be able to secure alternative sources of funding to do so.</p><p>The company had in May offered to privatise Catalist-listed Singapore Paincare at S$0.16 per share, representing a premium of 27 per cent over its last traded price then. But it was below its initial public offering price of S$0.22 per share in 2020.</p><p>The deal drew attention in August when the Securities Investors Association (Singapore), or Sias, flagged breaches of rule 8.6 on the code of takeovers and mergers, after Singapore Paincare shareholders received WhatsApp messages signed by its chief executive officer and chief operating officer prior to a meeting where they would vote on the privatisation.</p><p>One message summarised the offer and encouraged support for the delisting, and another reminded them of the proxy form deadline. Sias had called for the scheme meeting to be postponed and asked shareholders to resubmit their proxy forms.</p><p>Shares of Singapore Paincare last traded at S$0.159 on Nov 25, before a trading halt. Trading will resume on Dec 8.</p></div></div>

新加坡疼痛護理集團

<p>新加坡疼痛護理集團的私有化競標因提議方未能在 11 月 27 日前滿足計劃條件而失敗。與大華銀行的信貸設施已失效，提議方缺乏實施該計劃的財務資源。該競標價格為每股 0.16 新元，低於首次公開募股價格。新加坡投資者協會在八月份指出了規則違規行為。交易將於 12 月 8 日恢復</p>

新加坡疼痛護理集團的私有化收購提案未能成功，因為提議方未能在截止日期前滿足相關條件